Related Experiment Video
Updated: Feb 8, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Angiotensin-(1-9) ameliorates pulmonary arterial hypertension via angiotensin type II receptor
Seung Ah Cha1, Byung Mun Park1, Suhn Hee Kim1
1Department of Physiology, Research Institute for Endocrine Sciences, Chonbuk National University Medical School, Jeonju 54907, Korea.
Insights
Angiotensin-(1-9) [Ang-(1-9)] administration reduced pulmonary hypertension in rats by mitigating vascular remodeling, apoptosis, and inflammation via the Angiotensin type 2 receptor (AT2R). This peptide shows promise for treating pulmonary hypertension.
Area of Science:
- Cardiovascular Research
- Pulmonary Medicine
- Renal Physiology
Background:
- Angiotensin-(1-9) [Ang-(1-9)] is known for protective effects on cardiac and vascular remodeling.
- The impact of Ang-(1-9) on pulmonary hypertension has not been previously reported.
Purpose of the Study:
- To investigate the potential of Ang-(1-9) in improving pulmonary vascular remodeling in a rat model of monocrotaline (MCT)-induced pulmonary hypertension.
Main Methods:
- Sprague-Dawley rats were treated with Ang-(1-9) or saline via osmotic mini-pumps for 3 weeks.
- Pulmonary hypertension was induced by subcutaneous injection of MCT.
- Hemodynamic parameters, vascular remodeling, fibrosis, and molecular markers of apoptosis and inflammation were assessed.
Main Results:
- Ang-(1-9) administration significantly reduced right ventricular hypertrophy and systolic pressure in MCT-induced pulmonary hypertensive rats.
- Ang-(1-9) attenuated pulmonary arteriolar endothelial damage, medial hypertrophy, and fibrosis.
- Protective effects were mediated via the Angiotensin type 2 receptor (AT2R) and involved reduced levels of inflammatory cytokines and apoptosis-related proteins.
Conclusions:
- Angiotensin-(1-9) demonstrates significant therapeutic potential for mitigating MCT-induced pulmonary hypertension.
- The mechanism involves the downregulation of apoptosis and inflammatory responses through the AT2R pathway.
- Ang-(1-9) represents a promising novel therapeutic agent for pulmonary hypertension.
Abstract:
Angiotensin-(1-9) [Ang-(1-9)], generated from Ang I by Ang II converting enzyme 2, has been reported to have protective effects on cardiac and vascular remodeling. However, there is no report about the effect of Ang-(1-9) on pulmonary hypertension. The aim of the present study is to investigate whether Ang-(1-9) improves pulmonary vascular remodeling in monocrotaline (MCT)-induced pulmonary hypertensive rats. Sprague-Dawley rats received Ang-(1-9) (576 µg/kg/day) or saline via osmotic mini-pumps for 3 weeks. Three days after implantation of osmotic mini-pumps, 50 mg/kg MCT or vehicle were subcutaneously injected. MCT caused increases in right ventricular weight and systolic pressure, which were reduced by co-administration of Ang-(1-9). Ang-(1-9) also attenuated endothelial damage and medial hypertrophy of pulmonary arterioles as well as pulmonary fibrosis induced by MCT. The protective effects of Ang-(1-9) against pulmonary hypertension were inhibited by Ang type 2 receptor (AT2R) blocker, but not by Mas receptor blocker. Additionally, the levels of LDH and inflammatory cytokines, such as TNF-α, MCP-1, IL-1β, and IL-6, in plasma were lower in Ang-(1-9) co-treated MCT group than in vehicle-treated MCT group. Changes in expressions of apoptosis-related proteins such as Bax, Bcl-2, Caspase-3 and -9 in the lung tissue of MCT rats were attenuated by the treatment with Ang-(1-9). These results indicate that Ang-(1-9) improves MCT-induced pulmonary hypertension by decreasing apoptosis and inflammatory reaction via AT2R.
Related Concept Videos
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

